Browsing: Disease Area > Prostate
A test that is able to detect trace levels of circulating tumor cells could help spot the early signs of treatment not working for advanced prostate cancer patients.
Researchers have uncovered a key mechanism that drives hormone therapy resistance in prostate cancer.
A genetic test could aid the identification of men with prostate cancer who are most likely to benefit from immunotherapy.
The prostate cancer test combines genetic variations linked to prostate cancer and identifies the 1% of men that are at high risk.
Analysis of data from more than 8000 men with advanced prostate cancer who received chemotherapy suggests survival chances for black men are at least as good as those for white men when provided with equal treatment.
A prospective clinical trial, involving 100 men with metastatic castration-resistant prostate cancer, has demonstrated that black men experience a greater and longer lasting response to the hormone treatment abiraterone compared with white men.
A study conducted out by Cancer Research UK has discovered that carrying out one-off PSA tests on asymptomatic men does not reduce prostate cancer deaths.
Three hospitals in the UK are trialing a ‘one-stop’ prostate cancer diagnosis service, which is expected to reduce the time taken for a diagnosis from approximately 6 weeks to just days.